Evaluation of the effect of crocin in the treatment of cystoid macular edema secondary to retinitis pigmentosa

Evaluation of the effect of crocin in the treatment of cystoid macular edema secondary to retinitis pigmentosa : randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201219049753N2

Enrollment

Registered

2022-09-12

Start date

2022-09-22

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinitis pigmentosa. Hereditary retinal dystrophy

Interventions

Intervention 1: Intervention group :Patients with typical retinitis pigmentosa, over 18 years of age, who have macular cystoid edema (CMT above 296 microns in OCT or the presence of cysts in OCT) and

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with typical retinitis pigmentosa with increased central macular thickness They have not received treatment for this condition in the last 3 months They have the ability to understand the study and the power to choose to participate in the study.

Exclusion criteria

Exclusion criteria: History of diabetes Recent ocular surgery pregnancy and lactation period History of taking drugs that cause macular edema in the last 3 months Suffering from other eye diseases that lead to macular cystoid edema

Design outcomes

Primary

Measure	Time frame
The CMT in OCT. Timepoint: The central thickness of the macula in OCT at the beginning of the study before the intervention and at the end of the first, second and third month. Method of measurement: Macular OCT.;Size of cysts in the macula oct. Timepoint: At the beginning of the study before the intervention and at the end of the first, second and third month. Method of measurement: macula oct.	—

Secondary

Measure	Time frame
Best corrected visual acuity (BCVA). Timepoint: Best corrected visual acuity (BCVA) at the beginning of the study before the intervention and at the end of the first, second and third month. Method of measurement: Optometry.;Liver function tests. Timepoint: before the intervention and at the end of the study. Method of measurement: chemistry analyzer.;Kidney function tests. Timepoint: before the intervention and at the end of the study. Method of measurement: chemistry analyzer.;Fasting blood lipid profile. Timepoint: before the intervention and at the end of the study. Method of measurement: chemistry analyzer.;Fasting blood sugar. Timepoint: before the intervention and at the end of the study. Method of measurement: chemistry analyzer.;Complete blood count. Timepoint: before the intervention and at the end of the study. Method of measurement: hematology analyzer.	—

Measure

Time frame

Best corrected visual acuity (BCVA). Timepoint: Best corrected visual acuity (BCVA) at the beginning of the study before the intervention and at the end of the first, second and third month. Method of measurement: Optometry.;Liver function tests. Timepoint: before the intervention and at the end of the study. Method of measurement: chemistry analyzer.;Kidney function tests. Timepoint: before the intervention and at the end of the study. Method of measurement: chemistry analyzer.;Fasting blood lipid profile. Timepoint: before the intervention and at the end of the study. Method of measurement: chemistry analyzer.;Fasting blood sugar. Timepoint: before the intervention and at the end of the study. Method of measurement: chemistry analyzer.;Complete blood count. Timepoint: before the intervention and at the end of the study. Method of measurement: hematology analyzer.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehdi eslami shoabjareh

Mashhad University of Medical Sciences

mehdi1989eslami@gmail.com+98 51 3728 1401

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026